|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Investments at fair value | |||||||||||||||||
| Non-control/non-affiliate investments | |||||||||||||||||
| Affiliate investments | |||||||||||||||||
| Investment Affiliated Issuer Controlled | |||||||||||||||||
| U.S. Treasury Bills | |||||||||||||||||
| Total investments at fair value | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Interest and fees receivable | |||||||||||||||||
| Deferred financing costs on credit facility | |||||||||||||||||
| Total deferred financing costs on credit facility | |||||||||||||||||
| Other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities | |||||||||||||||||
| Credit facility | |||||||||||||||||
| Notes | |||||||||||||||||
| Proceeds from 2026 Notes | |||||||||||||||||
| 2027 Notes | |||||||||||||||||
| 2028 Notes | |||||||||||||||||
| 2029 Notes | |||||||||||||||||
| 2031 Notes | |||||||||||||||||
| Unamortized deferred financing costs | |||||||||||||||||
| Deferred financing costs | |||||||||||||||||
| Deferred financing costs, net | |||||||||||||||||
| Total debt, less DFC, discounts and premiums, net | |||||||||||||||||
| Distributions payable | |||||||||||||||||
| Incentive fees payable | |||||||||||||||||
| Interest payable | |||||||||||||||||
| Foreign currency forward contracts | |||||||||||||||||
| Secured borrowings | |||||||||||||||||
| Accrued expenses and other liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Net assets | |||||||||||||||||
| Common stock, par value | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Accumulated undistributed (overdistributed) earnings | |||||||||||||||||
| Treasury stock | |||||||||||||||||
| Total net assets | |||||||||||||||||
| Shares of common stock outstanding ($0.01 par value, 100,000,000 shares authorized) | |||||||||||||||||
| Net asset value per share | |||||||||||||||||
Loading...